Literature DB >> 10339068

A medication use evaluation of alendronate: compliance with administration guidelines.

T Mersfelder1, J A Armitstead, M F Ivey, M Cedars.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10339068

Source DB:  PubMed          Journal:  Pharm Pract Manag Q        ISSN: 1080-5737


× No keyword cloud information.
  6 in total

1.  Observational study of compliance and continuance rates of raloxifene in the prevention and treatment of osteoporosis.

Authors:  José R Zanchetta; Carina Hakim; Carola Lombas
Journal:  Curr Ther Res Clin Exp       Date:  2004-11

2.  Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world.

Authors:  H Ideguchi; S Ohno; H Hattori; Y Ishigatsubo
Journal:  Osteoporos Int       Date:  2007-06-19       Impact factor: 4.507

3.  The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis.

Authors:  Yuxiang Yan; Wei Wang; Hanmin Zhu; Mei Li; Jianli Liu; Bangyao Luo; Haibao Xie; Guangjian Zhang; Fuobao Li
Journal:  J Bone Miner Metab       Date:  2009-04-03       Impact factor: 2.626

Review 4.  A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate.

Authors:  Jean-Yves Reginster; Dieter Felsenberg; Cyrus Cooper; Jacob A Stakkestad; Paul D Miller; David L Kendler; Silvano Adami; Michael R McClung; Michael A Bolognese; Roberto Civitelli; Etienne Dumont; Bernard Bonvoisin; Robert R Recker; Pierre D Delmas
Journal:  Osteoporos Int       Date:  2005-06-14       Impact factor: 4.507

Review 5.  Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.

Authors:  Raja S Bobba; Karen Beattie; Bill Parkinson; Dinesh Kumbhare; Jonathan D Adachi
Journal:  Drug Saf       Date:  2006       Impact factor: 5.228

Review 6.  Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis.

Authors:  María J Moro-Alvarez; Manuel Díaz-Curiel
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.